Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.6800 (-0.57%) ($8.6800 - $8.6800) on Mon. Mar. 7, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.43% (three month average) | RSI | 42 | Latest Price | $8.6800(-0.57%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(77%) ARKG(72%) IBB(69%) ARKK(66%) IBUY(61%) | Factors Impacting TGTX price | TGTX will decline at least -3.715% in a week (0% probabilities). VIXM(-47%) VXX(-39%) UUP(-26%) TBT(-12%) EDOC(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.715% (StdDev 7.43%) | Hourly BBV | -1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-3.04(-135.02%) | Resistance Level | $10.08 | 5 Day Moving Average | $9.48(-8.44%) | 10 Day Moving Average | $9.62(-9.77%) | 20 Day Moving Average | $10.08(-13.89%) | To recent high | -57.5% | To recent low | 2.4% | Market Cap | $1.099b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |